GILD(Gilead Sciences, Inc.) 的财务报表:医疗保健,综合制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| 毛利润 | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B |
| 营业利润 | $9.92B | $7.33B | $7.61B | $1.66B | $10.02B |
| 净利润 | $6.22B | $4.59B | $5.67B | $480.00M | $8.51B |
| 经营现金流 | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B |
| 自由现金流 | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B |
| 摊薄每股收益 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |